Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed director

PLIANT THERAPEUTICS, INC. (PLRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "LEASE AGREEMENT",
"TERMINATION"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF"
08/07/2023 4 Hull Hans (Chief Business Officer) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Sold 13,069 shares @ $20, valued at $261.4k
Sold 1,800 shares @ $20, valued at $36k
Sold 20,050 shares @ $20.01, valued at $401.2k
Exercised 1,800 options to buy @ $2.08, valued at $3.7k
Exercised 8,791 options to buy @ $2.08, valued at $18.3k
08/03/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 144 Form 144 - Report of proposed sale of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2023 4 Ouimette Mike (General Counsel & Corp. Sec'y) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 27,187 shares @ $0
07/18/2023 4 Lefebvre Eric (Chief Medical Officer) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 43,750 shares @ $0
07/18/2023 4 Hull Hans (Chief Business Officer) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 35,156 shares @ $0
07/18/2023 4 Cummings Keith Lamont (CFO) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 38,750 shares @ $0
07/18/2023 4 Coulie Bernard (President and CEO) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 137,500 shares @ $0
06/12/2023 4 Cummings Keith Lamont (CFO) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Exercised 5,800 options to buy @ $2.08, valued at $12.1k
06/08/2023 4 Shah Smital (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 PYOTT DAVID E I (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 MCCOURT Thomas A (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 Knobil Katharine (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 Huh Hoyoung (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 Curnutte John T (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 CROWELL GAYLE A (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 Cline Darren S (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 4 Bruhn Suzanne Louise (Director) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Granted 14,000 options to buy @ $23.09, valued at $323.3k
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results"
05/01/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 4 Ouimette Mike (General Counsel & Corp. Sec'y) has filed a Form 4 on PLIANT THERAPEUTICS, INC.
Txns: Sold 4,874 shares @ $26.5209, valued at $129.3k
Sold 2,677 shares @ $26.7371, valued at $71.6k
Sold 200 shares @ $27.455, valued at $5.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy